The news of Care A2 Plus IPO garnered all of three posts on the HC A2M thread ... this is what they thought of it:
"It's been around in Aus a few years, has very low sales and market penetration here. The main point of differentiation is they add lactoferrin to their A2 formula (similar to A2 China label product).
It is owned and (until now) funded by a large multinational mining company based in the US, and got approval to sell in the US during the FDA's temporary enforcement freeze.
I say 'until now' because after they go public, it will be shareholders funding what looks like a very low margin / high cost business."
--------------
"Recent article about the competition ' Care A2+.' WHat a joke of a company.
"Care has a factory in Victoria and secured distribution through Chemist Warehouse, Woolworths and Terry White Chemists, among others, the prospectus said. Care A2 had only $365,918 revenue in the year to June 30, the prospectus said, and reported a $5.3 million loss in the financial year."
For every $1 of product the sold, they lost more than $10. Terrible business company compared to a2, and aiming for a market cap of 400 million"
----------
"Yeah this is what I was getting at in my response to the other poster earlier. I guess private equity has had enough of bleeding cash and they are trying to use the temporary FDA approval to rope shareholders into what is clearly an atrociously performing business. FYI the article says they are aiming at a $520M - $544M (AUD) market cap - what a joke!"